Incorporated in 2003, Nanobiotix is a leading, late clinical-stage nanomedicine company pioneering new approaches to significantly change patient outcomes by bringing nanophysics to the heart of the cell.

The Nanobiotix philosophy is one rooted in designing pioneer physical based approaches to bring highly effective and generalized solutions to address high unmet medical needs and challenges.   

Nanobiotix’s novel first-in-class, proprietary lead technology, NBTXR3, aims to expand radiotherapy benefits for millions of cancer patients. Furthermore, Nanobiotix’s Immuno-Oncology program has the potential to bring a new dimension to cancer immunotherapies. 

Nanobiotix is listed on the regulated market of Euronext in Paris (Euronext: NANO / ISIN: FR0011341205; Bloomberg: NANO: FP) and on the Nasdaq Global Select Market (Nasdaq: NBTX). The Company’s headquarters are based in Paris, France, with a U.S. affiliate in Cambridge, MA, and European affiliates in Spain and Germany. More: www.nanobiotix.com

Bpifrance

European Investment Bank

Johnson & Johnson Innovation – JJDC

Amorçage Rhône Alpes

Apicap

Karista

Matignon Technologies

Seventure Partners

Crédit Mutuel Innovation

Nanobiotix

LianBio, partenaire de Nanobiotix, transfère ses droits de développement et de commercialisation de NBTXR3 en Chine et sur d'autres marchés asiatiques. PR : https://lnkd.in/e6ATUM7T

Nanobiotix partner LianBio assigns its development and commercialization rights for NBTXR3 in China and other Asian Markets. PR link: https://lnkd.in/eE6vkSkq

Avec toute notre gratitude pour votre soutien afin de révolutionner le traitement de millions de patients à travers le monde, nous vous souhaitons de joyeuses fêtes à tous !

With gratitude for your support in revolutionizing treatment for millions of patients, we offer happy holidays to all!

Happy Thanksgiving to all of our friends, colleagues, supporters and patients in the United States. We are inspired by the spirit of Thanksgiving as we reflect on the important progress our incredible team has achieved this year toward achieving our mission of revolutionizing treatment for millions. Best wishes and enjoy the holiday!

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has a partnership with LianBio to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. The company was incorporated in 2003 and is headquartered in Paris, France.

Nanobiotix S.A.

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

COM:NANOBIOTIX

Nanobiotix

Last Close

3.50

25/11 09:24

Market Cap

237.91M

Beta: -

Volume Today

19.84K

Avg: -

news impact assignment basic	general
public peers	general
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general
crunchbase trigger	general	Nov 27, 2024 12:50 PM	e9465d51
crunchbase profile	general
li profile	general	Jan 29, 2024 11:06 PM	90d1b83a
translate crunchbase fundingrounds	general
peers	general
news basic	general
bundesanzeiger	filings
financials download nd	financials
private financials	financials